Chemotherapy of increasing intensity in the treatment of chronic myelomonocytic leukemia (CMML).

被引：0
|
作者：
Beran, M [1 ]
Onida, F [1 ]
Cortes, JE [1 ]
O'Brien, S [1 ]
Giles, FJ [1 ]
Estey, E [1 ]
Keating, MJ [1 ]
Koller, CA [1 ]
Kantarjian, HM [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2614
引用
收藏
页码：624A / 624A
页数：1
相关论文
共 50 条
  • [21] Chronic myelomonocytic leukemia (CMML) associated with symptomatic pericardial effusion.
    Ibrahim, M. I.
    Maslak, P. G.
    Heaney, M. L.
    George, M. S.
    Downey, R. J.
    Tallman, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Treatment Outcomes and Prognostic Factors in 66 Patients with Chronic Myelomonocytic Leukemia (CMML) in a Single Center
    Wang, Chao
    Wang, Zhiqiong
    Meng, Fankai
    Luo, Li
    Liu, Xian
    Shi, Jiayu
    Huang, Lifang
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2022, 15 : 7843 - 7854
  • [23] Incidence and survival of chronic myelomonocytic leukemia (CMML) in the United States (US).
    Murthy, Guru Subramanian Guru
    Venkitachalam, Raji
    Bhatt, Vijaya Raj
    Dhakal, Ishwori
    Lee, Jeanette Y.
    Jethava, Yogesh
    Mehta, Paulette
    Emanuel, Peter D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Characterization of Chronic Myelomonocytic Leukemia (CMML) with Preexisting Myeloproliferative Neoplasm (MPN)
    Xu, Y.
    Yung, A.
    Kwok, B.
    MacDonell, K.
    Dabbas, B.
    Reddy, P.
    MODERN PATHOLOGY, 2014, 27 : 386A - 386A
  • [25] Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale
    Ramadan, Hanadi
    Duong, Vu H.
    Al Ali, Najla
    Padron, Eric
    Zhang, Ling
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 : S64 - S66
  • [26] A Phase II Trial of Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Thrombocytopenia
    Itzykson, Raphael
    Lambert, Jerome
    Barbieri, Daniela
    Gruson, Berengere
    Thepot, Sylvain
    Braun, Thorsten
    Vey, Norbert
    Delaunay, Jacques
    Legros, Laurence
    Lejeune, Julie
    Sapena, Rosa
    Droin, Nathalie
    Porteu, Francoise
    Solary, Eric
    Fenaux, Pierre
    BLOOD, 2017, 130
  • [27] Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents
    Venugopal, Sangeetha
    Chien, Kelly S.
    Hammond, Danielle
    Kanagal-Shamanna, Rashmi
    Sasaki, Koji
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Konopleva, Marina
    Daver, Naval
    Ravandi, Farhad
    Pemmaraju, Naveen
    Short, Nicholas J.
    Issa, Ghayas C.
    Takahashi, Koichi
    Estrov, Zeev E.
    Pierce, Sherry A.
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    BLOOD, 2021, 138
  • [28] Chronic Myelomonocytic Leukemia (CMML) Can be Categorized By Ancestral Mutational Events
    Patel, Bhumika J.
    Huang, Dayong
    Thota, Swapna
    Przychodzen, Bartlomiej P.
    Sakaguchi, Hirotoshi
    Kojima, Seiji
    Ogawa, Seishi
    Sekeres, Mikkael A.
    Makishima, Hideki
    Maciejewski, Jaroslaw P.
    BLOOD, 2014, 124 (21)
  • [29] Characterization of Chronic Myelomonocytic Leukemia (CMML) with Preexisting Myeloproliferative Neoplasm (MPN)
    Xu, Y.
    Yung, A.
    Kwok, B.
    MacDonell, K.
    Dabbas, B.
    Reddy, P.
    LABORATORY INVESTIGATION, 2014, 94 : 386A - 386A
  • [30] AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): POSSIBILITY OF IMPROVED RESPONSE AND SURVIVAL
    Niscola, P.
    Tendas, A.
    Cupelli, L.
    Piccioni, D.
    Giovannini, M.
    Scaramucci, L.
    Abruzzese, E.
    Caravita, T.
    Dentamaro, T.
    Morino, L.
    Neri, B.
    Renzi, D.
    Siniscalchi, A.
    Trawinska, M. M.
    de Fabritiis, P.
    HAEMATOLOGICA, 2015, 100 : 727 - 727
12345